LifeStance Health Group, Inc. Earnings Per Share Disclosure
NOTE 13 EARNINGS PER SHARE
The following table presents the calculation of basic and diluted earnings (loss) per share for the Company’s common shares:
|
|
Year Ended December 31, |
|
|||||||||
|
|
2025 |
|
|
2024 |
|
|
2023 |
|
|||
Numerator |
|
|
|
|
|
|
|
|
|
|||
Net income (loss) available to common stockholders' |
|
$ |
9,663 |
|
|
$ |
(57,443 |
) |
|
$ |
(186,262 |
) |
Denominator |
|
|
|
|
|
|
|
|
|
|||
Weighted-average shares - basic |
|
|
386,016 |
|
|
|
379,147 |
|
|
|
367,457 |
|
Dilutive effect of outstanding stock-based awards |
|
|
5,120 |
|
|
|
— |
|
|
|
— |
|
Weighted-average shares - diluted |
|
|
391,136 |
|
|
|
379,147 |
|
|
|
367,457 |
|
Earnings (loss) per share |
|
|
|
|
|
|
|
|
|
|||
Basic |
|
$ |
0.03 |
|
|
$ |
(0.15 |
) |
|
$ |
(0.51 |
) |
Diluted |
|
$ |
0.02 |
|
|
$ |
(0.15 |
) |
|
$ |
(0.51 |
) |
The Company has issued potentially dilutive instruments in the form of RSAs, RSUs and stock options. The following potentially dilutive shares are excluded from the computation of diluted earnings (loss) per share for the periods presented because including them would have been anti-dilutive:
|
|
As of December 31, |
|
|||||||||
|
|
2025 |
|
|
2024 |
|
|
2023 |
|
|||
RSAs, RSUs and stock options |
|
|
34,335 |
|
|
|
39,734 |
|
|
|
42,333 |
|
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 25, 2026 | Showing above |
| 2022 | Mar 9, 2023 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.